News - Celgene

Filter

Current filters:

Celgene

Popular Filters

40 to 64 of 91 results

MorphoSys and Celgene in deal to advance MOR202 for multiple myeloma

27-06-2013

German biotech firm MorphoSys (FSE: MOR) and USA-based Celgene (Nasdaq: CELG), the world's largest independent…

BiotechnologyCelgeneEuropeLicensingMergers & AcquisitionsMOR202MorphoSysOncology

Bionor Pharma leaps on positive trial results of HIV vaccine Vacc-4x with Revlimid

14-06-2013

Norway-based Bionor Pharma (OSE: BIONOR) saw its shares leap 16% to 3.67 kroner on June 13, after the…

Anti-viralsBionor PharmaCelgenePharmaceuticalResearchRevlimidVacc-4xVaccines

US FDA backs new indication for Celgene's Revlimid

06-06-2013

The US Food and Drug Administration has approved US biotech firm Celgene's (Nasdaq: CELG) supplemental…

BiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

Latest news from ASCO: Celgene's Revlimid; AbbVie's ABT-199; DelMar's VAL-083

04-06-2013

Continuing our coverage of the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AbbVieABT-199CelgeneDelMar PharmaceuticalsOncologyPharmaceuticalResearchRevlimidVAL-083

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Celgene partners with FORMA Thera on drugs targeting protein homeostasis

30-04-2013

Privately-held FORMA Therapeutics has entered into a strategic collaboration agreement with US biotech…

BiotechnologyCelgeneFORMA TherapeuticsLicensingNeurologicalOncologyResearch

Celgene 1st-qtr revenues leap 15% but profit falls 4%

28-04-2013

US biotech firm Celgene (Nasdaq: CELG) last week posted first-quarter 2013 financial results, showing…

BiotechnologyCelgeneFinancial

Cyclacel sells four disputed romidepsin-related patents to Celgene

05-04-2013

USA based Cyclacel Pharmaceuticals (Nasdaq: CYCC) says that it has entered into a definitive agreement…

BiotechnologyCelgeneCyclacel PharmaceuticalsLegalOncologyPatentsromidepsin

bluebird bio in multi-million dollar oncology deal with Celgene

22-03-2013

In a second licensing accord this month, US biotech firm Celgene Corp (Nasdaq: CELG) has signed a strategic…

Biotechnologybluebird bioCelgeneLicensingOncology

Presage Biosciences in deal with Celgene on novel cancer drug combinations

06-03-2013

Privately-held USA-based cancer drug developer Presage Biosciences has entered into a strategic collaboration…

BiotechnologyCelgeneLicensingOncologyPresage Biosciences

AAD conference briefs: Celgene's apremilast; and Sanofi's dupilumab

04-03-2013

The European subsidiary of US biotech firm Celgene Corp (Nasdaq: CELG) presented the results from ESTEEM…

apremilastBiotechnologyCelgeneDermatologicalsdupilumabPharmaceuticalRegeneronResearchSanofi

Chelsea Thera to re-file Northera NDA with existing data; Celgene share buyback

21-02-2013

Chelsea Therapeutics International (Nasdaq: CHTP) saw its shares more than double to $1.61 in pre-market…

BiotechnologyCardio-vascularCelgeneChelsea TherapeuticsFinancialNorth AmericaNortheraRegulation

Celgene's Revlimid approved in China for MM; gets PDUFA date in USA for mantle cell lymphoma

12-02-2013

Celgene Corp's (Nasdaq: CELG) European subsidiary revealed that Revlimid (lenalidomide) has been granted…

Asia-PacificBiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

FDA approves Celgene's Pomalyst for advanced multiple myeloma

11-02-2013

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Pomalyst…

BiotechnologyCelgeneNorth AmericaOncologypomalidomidePomalystRegulation

Celgene post strong sales and earnings performance

25-01-2013

US biotech company Celgene (Nasdaq: CELG) yesterday reported net product sales of $1.42 billion for the…

BiotechnologyCelgeneFinancial

Celgene's Abraxane plus gemcitabine extends survival in pancreatic cancer patients

23-01-2013

US biotech firm Celgene Corp (Nasdaq: CELG) says that its Phase III clinical trial of Abraxane (nab-paclitaxel)…

AbraxaneBiotechnologyCelgenegemcitabine HclOncologyResearch

News briefs: Celgene deal with Sutro; Amgen pleads guilty to misbranding

19-12-2012

US biotech firm Celgene Corp (Nasdaq: CELG) has entered a collaboration with San Francisco-based Sutra…

AmgenAranespBiotechnologyCelgeneFinancialLegalLicensingNorth AmericaSutro Biopharma

TGen, Scottsdale Healthcare study Abraxane combo for pancreatic cancer

20-11-2012

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage…

AbraxaneBiotechnologyCelgeneOncologyResearch

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene

19-11-2012

There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…

BexseroBiotechnologyCelgeneDiabetesEuropeIstodaxLyxumiaNovartisOncologyPharmaceuticalRegulationSanofiVaccinesZaltrap

Celgene's Abraxane meets primary endpoints in pancreatic cancer study

13-11-2012

In what was some good news on the pancreatic cancer scene, the European subsidiary of US biotech firm…

AbraxaneBiotechnologyCelgeneOncologyResearch

Celgene beats sales forecasts with strong third-quarter results

26-10-2012

US biotech company Celgene (Nasdaq; CELG) reported total revenue of $1.42 billion for the third quarter…

BiotechnologyCelgeneFinancial

40 to 64 of 91 results

Back to top